<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Med Sci Monit</journal-id><journal-id journal-id-type="iso-abbrev">Med. Sci. Monit</journal-id><journal-id journal-id-type="publisher-id">Medical Science Monitor</journal-id><journal-title-group><journal-title>Medical Science Monitor : International Medical Journal of Experimental and Clinical Research</journal-title></journal-title-group><issn pub-type="ppub">1234-1010</issn><issn pub-type="epub">1643-3750</issn><publisher><publisher-name>International Scientific Literature, Inc.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25391977</article-id><article-id pub-id-type="doi">10.12659/MSM.892413</article-id><article-id pub-id-type="publisher-id">892413</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Research</subject></subj-group></article-categories><title-group><article-title>Matrix Metalloproteinase 1, 3, and 9 Polymorphisms and Esophageal Squamous Cell Carcinoma Risk</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Guan</surname><given-names>Xuan</given-names></name><xref ref-type="aff" rid="af1-medscimonit-20-2269">1</xref><xref ref-type="aff" rid="af2-medscimonit-20-2269">2</xref><xref ref-type="author-notes" rid="fn2-medscimonit-20-2269">B</xref><xref ref-type="author-notes" rid="fn3-medscimonit-20-2269">C</xref><xref ref-type="author-notes" rid="fn4-medscimonit-20-2269">D</xref><xref ref-type="author-notes" rid="fn5-medscimonit-20-2269">E</xref><xref ref-type="author-notes" rid="fn8-medscimonit-20-2269">*</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Xiang</given-names></name><xref ref-type="aff" rid="af3-medscimonit-20-2269">3</xref><xref ref-type="author-notes" rid="fn4-medscimonit-20-2269">D</xref><xref ref-type="author-notes" rid="fn8-medscimonit-20-2269">*</xref></contrib><contrib contrib-type="author"><name><surname>Luo</surname><given-names>Hao</given-names></name><xref ref-type="aff" rid="af4-medscimonit-20-2269">4</xref><xref ref-type="author-notes" rid="fn3-medscimonit-20-2269">C</xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Jing</given-names></name><xref ref-type="aff" rid="af2-medscimonit-20-2269">2</xref><xref ref-type="author-notes" rid="fn2-medscimonit-20-2269">B</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Xiao</given-names></name><xref ref-type="aff" rid="af1-medscimonit-20-2269">1</xref><xref ref-type="author-notes" rid="fn7-medscimonit-20-2269">G</xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Jin</given-names></name><xref ref-type="aff" rid="af2-medscimonit-20-2269">2</xref><xref ref-type="author-notes" rid="fn1-medscimonit-20-2269">A</xref><xref ref-type="corresp" rid="c1-medscimonit-20-2269"/></contrib></contrib-group><aff id="af1-medscimonit-20-2269"><label>1</label>School of Basic Medical Sciences, Chengdu Medical College, Chengdu, Sichuan, China</aff><aff id="af2-medscimonit-20-2269"><label>2</label>Department of Forensic Biology, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, Sichuan, China</aff><aff id="af3-medscimonit-20-2269"><label>3</label>Primary Care Center, Sichuan Provincial People&#x02019;s Hospital, Chengdu, Sichuan, China</aff><aff id="af4-medscimonit-20-2269"><label>4</label>Nursing Department, Leshan Vocational, Leshan, Sichuan, China</aff><author-notes><corresp id="c1-medscimonit-20-2269">Corresponding Author: Jin Wu, e-mail: <email>wujin20128@163.com</email></corresp><fn id="fn1-medscimonit-20-2269"><label>A</label><p>Study Design</p></fn><fn id="fn2-medscimonit-20-2269"><label>B</label><p>Data Collection</p></fn><fn id="fn3-medscimonit-20-2269"><label>C</label><p>Statistical Analysis</p></fn><fn id="fn4-medscimonit-20-2269"><label>D</label><p>Data Interpretation</p></fn><fn id="fn5-medscimonit-20-2269"><label>E</label><p>Manuscript Preparation</p></fn><fn id="fn6-medscimonit-20-2269"><label>F</label><p>Literature Search</p></fn><fn id="fn7-medscimonit-20-2269"><label>G</label><p>Funds Collection</p></fn><fn id="fn8-medscimonit-20-2269"><label>*</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>13</day><month>11</month><year>2014</year></pub-date><volume>20</volume><fpage>2269</fpage><lpage>2274</lpage><history><date date-type="received"><day>06</day><month>9</month><year>2014</year></date><date date-type="accepted"><day>13</day><month>10</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; Med Sci Monit, 2014</copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License</license-p></license></permissions><abstract><sec><title>Background</title><p>Matrix metalloproteinases (MMPs) are multifunctional zinc-dependent proteinases that play a fundamental role in the pathogenesis of tumors. We have analyzed the association between 3 single-nucleotide polymorphisms (SNPs; <italic>MMP1</italic> &#x02212;1607 1G/2G, <italic>MMP3</italic> &#x02212;1612 5A/6A, and <italic>MMP9</italic> &#x02212;1562 C/T) and the risk of esophageal squamous cell carcinoma (ESCC).</p></sec><sec><title>Material/Methods</title><p>We investigated these 3 SNPs in 132 patients and 132 controls using polymerase chain reaction-restriction fragment length polymorphism methods. The <italic>MMP1</italic> and <italic>MMP3</italic> genes are located on the same chromosome. Haplotype analysis was performed to study the combined effect of the linked <italic>MMP</italic> polymorphisms on ESCC risk.</p></sec><sec><title>Results</title><p>The <italic>MMP1</italic> and <italic>MMP9</italic> promoter polymorphisms were not associated with ESCC risk, while the <italic>MMP3</italic> &#x02212;1612 5A/6A polymorphism was significantly associated with susceptibility to ESCC. Patients carrying the 5A allele had a significantly higher risk for developing ESCC compared with individuals carrying the 6A allele (OR=1.93; 95% CI 1.34&#x02013;2.77; <italic>p</italic>&#x0003c;0.01). The 2G-5A and 1G-5A haplotypes were associated with a significantly increased risk of ESCC as compared with the 2G-6A haplotype (OR=2.04, 95% CI 1.37&#x02013;3.04 and OR=3.65, 95% CI 1.26&#x02013;10.55, respectively).</p></sec><sec><title>Conclusions</title><p>These findings implicate this <italic>MMP3</italic> polymorphism as a contributor to ESCC susceptibility.</p></sec></abstract><kwd-group><title>MeSH Keywords</title><kwd>Esophageal Neoplasms</kwd><kwd>Genetic Association Studies</kwd><kwd>Matrix Metalloproteinase 1</kwd></kwd-group></article-meta></front><body><sec><title>Background</title><p>Esophageal cancer is among the 10 most common cancers worldwide [<xref rid="b1-medscimonit-20-2269" ref-type="bibr">1</xref>]. Given its anatomical location, esophageal neoplasia is associated with considerable morbidity, and typical symptoms include progressive dysphagia and weight loss. The 2 major pathological types of esophageal cancer are esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) [<xref rid="b2-medscimonit-20-2269" ref-type="bibr">2</xref>].</p><p>China appears to have higher incidence of esophageal cancer than Western nations [<xref rid="b3-medscimonit-20-2269" ref-type="bibr">3</xref>,<xref rid="b4-medscimonit-20-2269" ref-type="bibr">4</xref>]. While the incidence of EAC in Western populations has recently risen and ESCC incidence has fallen [<xref rid="b5-medscimonit-20-2269" ref-type="bibr">5</xref>], ESCC remains the major esophageal malignancy in China. Alcohol consumption and tobacco smoking represent the most significant risk factors for the development of esophageal cancer [<xref rid="b6-medscimonit-20-2269" ref-type="bibr">6</xref>]. However, not all exposed individuals will develop neoplastic disease, suggesting that genetic factors may play key roles in esophageal cancer. Currently, single-nucleotide polymorphisms (SNPs) present in several genes have emerged as significant determinants of disease susceptibility.</p><p>Matrix metalloproteinases (MMPs) are a family of at least 20 proteolytic enzymes that play essential roles in cleaving extra cellular matrix (ECM) components. MMPs are classified into 6 subgroups (collagenases, stromelysins, gelatinizes, matrilysins membrane-type MMPs, and others,) on the basis of their structure and substrate specificity. <italic>MMP1</italic>, <italic>MMP3</italic>, and <italic>MMP9</italic>, represent different groups of MMPs: the collagenases, stromielysins, and gelatinases, respectively [<xref rid="b7-medscimonit-20-2269" ref-type="bibr">7</xref>], Overexpression of <italic>MMP1</italic>, <italic>MMP3</italic>, or <italic>MMP9</italic> is closely related to the pathogenesis of tissue-destructive processes in a range of diseases, including ESCC [<xref rid="b8-medscimonit-20-2269" ref-type="bibr">8</xref>&#x02013;<xref rid="b10-medscimonit-20-2269" ref-type="bibr">10</xref>].</p><p>Three polymorphisms have been identified at nucleotides &#x02212;1607 1G/2G, &#x02212;1612 5A/6A, and &#x02212;1562 C/T in the promoter regions of the <italic>MMP1</italic>, <italic>MMP3</italic>, and <italic>MMP9</italic> genes, respectively, and these have been demonstrated to have functional effects on promoter activity and subsequent gene expression [<xref rid="b11-medscimonit-20-2269" ref-type="bibr">11</xref>&#x02013;<xref rid="b13-medscimonit-20-2269" ref-type="bibr">13</xref>]. Multiple studies concerning the association of these polymorphisms with susceptibility to various malignancies have been conducted [<xref rid="b14-medscimonit-20-2269" ref-type="bibr">14</xref>&#x02013;<xref rid="b17-medscimonit-20-2269" ref-type="bibr">17</xref>], but their findings are inconsistent. Until now, only a few [<xref rid="b18-medscimonit-20-2269" ref-type="bibr">18</xref>,<xref rid="b19-medscimonit-20-2269" ref-type="bibr">19</xref>] reports concerning the involvement of these 3 polymorphisms in ESCC have been published. Therefore, the aim of this current study was to ascertain whether SNPs in the promoters of the <italic>MMP1</italic>, <italic>MMP3</italic>, and <italic>MMP9</italic> genes are associated with the risk of developing ESCC in a Chinese population.</p></sec><sec sec-type="materials|methods"><title>Material and Methods</title><sec sec-type="subjects"><title>Subjects</title><p>A total of 264 subjects were included in this study. Details of the case and control population have been described previously [<xref rid="b20-medscimonit-20-2269" ref-type="bibr">20</xref>]. Briefly, this study recruited 132 patients with ESCC and 132 healthy controls. All subjects were unrelated ethnic Han Chinese. Patients were consecutively recruited from January 2005 to September 2007 at the People&#x02019;s Hospital of Suining, Sichuan, China. Diagnosis of ESCC was confirmed by histopathological examination. The ESCC patient group included 74 males and 58 females, with a mean age at diagnosis of 60 years. There were no significant differences in age, sex distribution, or cigarette smoking status between the case group and control group, suggesting that the matching of participants was adequate. The study was approved by the Ethics Committee of the Sichuan Cancer Institute. Written informed consent was obtained from all participants. All participants completed a questionnaire concerning their personal history and smoking history.</p></sec><sec><title>Genotyping</title><p>Genomic DNA used for the experiment was extracted from peripheral blood by proteinase K digestion and phenol/chloroform extraction. Polymorphism presence was determined using a polymerase chain reaction-restriction fragment length polymorphism method. PCR reactions were carried out in a total volume of 25 &#x003bc;L containing 30&#x02013;40 ng of genomic DNA, 3.3 &#x003bc;L of 1 mol/l dNTP, 2.5 &#x003bc;L of 10 &#x000d7; PCR Buffer, 25 mM MgCl<sub>2</sub>, 0.3 &#x003bc;L each 10 pM primer, and 0.3 &#x003bc;L 2.5 U/&#x003bc;L Taq polymerase, with the remaining volume DDH<sub>2</sub>O. The details of primer sequences, annealing temperature, and restriction enzymes used are shown in <xref ref-type="table" rid="t1-medscimonit-20-2269">Table 1</xref>. PCR products were digested overnight at 37&#x000b0;C with 0.5 U of the indicated restriction enzyme. Digestion products were then analyzed directly by vertical non-denaturing polyacrylamide gel electrophoresis and visualized by silver staining. To confirm the genotyping results, PCR-amplified DNA samples were examined with DNA sequencing. No differences were found in either quality controls and the results were 100% concordant.</p></sec><sec sec-type="methods"><title>Statistical analysis</title><p>Genotype and allele frequencies were compared between patients and controls using the &#x003c7;<sup>2</sup> and Fisher&#x02019;s exact tests as appropriate. Tests of Hardy-Weinberg equilibrium were calculated with an observed genotype frequencies of fit &#x003c7;<sup>2</sup> test with 1 degree of freedom. The odds ratio (OR) and 95% confidence interval (CI) were calculated to assess the relative risk conferred by a particular allele and genotype. Statistical significance was set at <italic>p</italic>&#x0003c;.05. These analyses were performed using SPSS 15.0 software. Simultaneously, the <italic>MMP1</italic> &#x02212;1607 1G/2G and <italic>MMP3</italic> &#x02212;1612 5A/6A haplotype frequencies and linkage disequilibrium coefficient were estimated using the PHASE 2.0 program [<xref rid="b21-medscimonit-20-2269" ref-type="bibr">21</xref>].</p></sec></sec><sec sec-type="results"><title>Results</title><sec sec-type="intro|methods|subjects"><title>Characteristics of the study subjects</title><p>The characteristics of the 132 ESCC patients and 132 control subjects included in this study are summarized in <xref ref-type="table" rid="t2-medscimonit-20-2269">Table 2</xref>. No statistical differences in age and sex distribution were identified between ESCC patients and control individuals, suggesting that frequency-matching based on these variables was adequate. No family history of ESCC was reported among controls or cases.</p></sec><sec><title>The genotype and allele frequencies of MMPs</title><p>The genotype distributions in the total sample were present in Hardy-Weinberg equilibrium. The genotype and allele frequencies of the 3 SNPs (<italic>MMP1</italic> &#x02212;1607 1G/2G, <italic>MMP3</italic> &#x02212;1612 5A/6A, and <italic>MMP9</italic> &#x02212;1562 C/T) are summarized in <xref ref-type="table" rid="t3-medscimonit-20-2269">Table 3</xref>. For <italic>MMP3</italic> &#x02212;1612 5A/6A, there was a significant difference in the genotype and allele frequencies of this polymorphism between ESCC and control subjects. The 6A5A and 5A5A genotypes were associated with a significantly higher risk of ESCC as compared with the 6A6A genotype (OR=1.92; 95% CI 1.14&#x02013;3.23; <italic>p</italic>=.01 and OR=5.42; 95% CI 2.01&#x02013;14.63; <italic>p</italic>&#x0003c;0.01, respectively). Using the 6A allele as a reference, a significant correlation was detected between the presence of the 5A allele and a risk of developing ESCC (OR=1.93; 95% CI 1.34&#x02013;2.77; <italic>p</italic>&#x0003c;0.01). However, genotype and allele frequencies of the <italic>MMP1</italic> &#x02212;1607 1G/2G and <italic>MMP9</italic> &#x02212;1562 C/T polymorphisms in ESCC patients were not significantly different from those in healthy controls (<italic>p</italic>&#x0003e;.05). Since the <italic>MMP1</italic> and <italic>MMP3</italic> genes are located in the same chromosome region (11q22.3), haplotype analysis was calculated and the estimated haplotype frequencies are summarized in <xref ref-type="table" rid="t4-medscimonit-20-2269">Table 4</xref>. The results of 2LD analysis revealed that the <italic>MMP1</italic> &#x02212;1607 1G/2G and the <italic>MMP3</italic> &#x02212;1612 5A/6A polymorphisms displayed a linkage disequilibrium (D&#x02032;=0.51) in healthy subjects. Haplotype analysis indicated that 2G-6A was the most common haplotype in healthy controls (39.6%), followed by the 2G-5A (37.3%), 1G-6A (18.0%), and 1G-5A (5.1%) haplotypes. The 2G-5A and 1G-5A haplotypes were associated with a significantly increased risk of ESCC as compared with the 2G-6A haplotype (OR = 2.04, 95% CI 1.37&#x02013;3.04 and OR=3.65, 95% CI 1.26&#x02013;10.55, respectively). Our study demonstrated 86% (<italic>MMP1</italic> &#x02212;1607 1G/2G), 87% (<italic>MMP3</italic> &#x02212;1612 5A/6A), and 88% (<italic>MMP9</italic> &#x02212;1562 C/T) power to detect an effect with an odds ratio of 2.2 in cases versus controls under a dominant genetic model.</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>Our results appear to be in line with the well-documented functional relevance of the <italic>MMP3</italic> &#x02212;1612 5A/6A SNP. Accordingly, this suggests that <italic>MMP3</italic> gene polymorphisms may be useful genetic susceptibility markers for ESCC.</p><p>MMPs are a pivotal family of zinc-dependent enzymes that are involved in all stages of cancer progression. MMPs are considered to be particularly important for the invasion and metastasis processes of cancer cells, as these require proteolysis of the ECM and basement membrane. However, recent studies have reported that MMPs are involved in regulating tumor cell growth, apoptosis, invasion, cell adhesion, metastasis, angiogenesis, cell signaling, and immune surveillance [<xref rid="b22-medscimonit-20-2269" ref-type="bibr">22</xref>,<xref rid="b23-medscimonit-20-2269" ref-type="bibr">23</xref>]. In normal tissues, MMP levels are usually low. Accordingly, overexpression of <italic>MMP1</italic>, <italic>MMP3</italic>, or <italic>MMP9</italic> may contribute to the pathogenesis of tissue-destructive processes in ESCC. Functional studies indicate that the &#x02212;1607 1G/2G, &#x02212;1612 5A/6A, and &#x02212;1562 C/T polymorphisms affect <italic>MMP1</italic>, <italic>MMP3</italic>, and <italic>MMP9</italic> promoter activities, respectively.</p><p><italic>MMP9</italic>, also called gelatinase B and 92-kDa type IV collagenase, is involved in the breakdown of gelatin, collagens and elastin [<xref rid="b24-medscimonit-20-2269" ref-type="bibr">24</xref>]. To our knowledge, a link between the <italic>MMP9</italic> &#x02212;1562 C/T polymorphism and ESCC has not previously been established. Zhang et al. [<xref rid="b13-medscimonit-20-2269" ref-type="bibr">13</xref>] first reported that the <italic>MMP9</italic> &#x02212;1562 C/T polymorphism created a binding site for a transcriptional repressor protein. We therefore suspected that this functional polymorphism could be involved with ESCC pathogenesis. However, we did not find any link between the <italic>MMP9</italic> &#x02212;1562 C/T polymorphism and ESCC in this study.</p><p>The <italic>MMP1</italic> gene promoter carries a common deletion/insertion polymorphism at position &#x02212;1607. The 2G allele, as opposed to the 1G allele, is associated with the creation of a new 5&#x02032;-GGA-3&#x02032; core recognition sequence for the Ets family of transcription factors [<xref rid="b11-medscimonit-20-2269" ref-type="bibr">11</xref>]. Our finding was consistent with the findings of a previous report that found no association between the <italic>MMP1</italic> polymorphism and ESCC risk.</p><p>The <italic>MMP1</italic> (human collagenase-1) and <italic>MMP3</italic> (human stromelysin-1) genes are located in the same chromosome region (11q22.3). Both are produced by macrophages, stromal fibroblasts, and epithelial cells and <italic>MMP3</italic> exhibits proteolytic activity on numerous extracellular matrix proteins [<xref rid="b25-medscimonit-20-2269" ref-type="bibr">25</xref>]. Additionally, <italic>MMP3</italic> is capable of activating several other MMPs, including <italic>MMP1</italic> and <italic>MMP9</italic>. Moreover, <italic>MMP3</italic> can influence the secretion of some cell-surface molecules, including E-cadherin, and promote tumor formation and progression [<xref rid="b26-medscimonit-20-2269" ref-type="bibr">26</xref>]. The <italic>MMP3</italic> gene promoter has a dimorphism at position &#x02212;1172, where either 5 (5A allele) or 6 (6A allele) adenosine residues are found. Deletion of an adenosine (5A) leads to increased <italic>MMP3</italic> transcription compared with the 6A allele <italic>in vitro</italic> [<xref rid="b27-medscimonit-20-2269" ref-type="bibr">27</xref>]. Therefore, the presence of the <italic>MMP3</italic> &#x02212;1612 5A/6A polymorphism is associated with an increased risk of developing a range of cancers, including colorectal adenoma [<xref rid="b28-medscimonit-20-2269" ref-type="bibr">28</xref>], hepatocellular carcinoma [<xref rid="b29-medscimonit-20-2269" ref-type="bibr">29</xref>], and lung cancer [<xref rid="b30-medscimonit-20-2269" ref-type="bibr">30</xref>]. This study identified a higher frequency of the 5A allele in ESCC patients (OR 1.53; <italic>p</italic>=.035) when compared with controls. The frequency of the <italic>MMP3</italic> 5A allele among control Chinese individuals was 0.276, which was significantly lower than that reported in Austria (0.470) [<xref rid="b31-medscimonit-20-2269" ref-type="bibr">31</xref>], Italy (0.440) [<xref rid="b14-medscimonit-20-2269" ref-type="bibr">14</xref>], Czech Republic (0.483) [<xref rid="b32-medscimonit-20-2269" ref-type="bibr">32</xref>], and Sweden (0.536) [<xref rid="b32-medscimonit-20-2269" ref-type="bibr">32</xref>]. Zhang et al. [<xref rid="b33-medscimonit-20-2269" ref-type="bibr">33</xref>] indicated that the <italic>MMP3</italic> 5A allele was a significant risk factor for ESCC only in current or ex-smokers, suggesting that the effect of the <italic>MMP3</italic> &#x02212;1612 5A/6A polymorphism on ESCC might be influenced by cigarette smoking. In the current study, we found no evidence to support this.</p><p>There are several limitations to our study. Firstly, this was a hospital-based case-control study. Secondly, the subjects were not adjusted in our logistic regression models because of the lack of detailed information about their diet, alcohol consumption, and environmental data. Finally, we selected common SNPs within the same haplotype structure instead of haplotype tagging SNPs, and the selection criteria for the candidate polymorphisms were based on evidence of putative functional change. This strategy may lead to inherited error in the analysis, and further studies with larger samples are needed to explore this further.</p><p>In summary, our research provides evidence that the <italic>MMP3</italic> &#x02212;1612 5A/6A polymorphism is a genetic susceptibility factor for the development of ESCC in a Chinese population. Additionally, the 2G-5A and 1G-5A haplotypes are associated with a higher risk of ESCC. Further studies in diverse ethnic populations are needed to verify our results, and an evaluation of gene-environment interactions on the risk of ESCC development would also be of great value.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>These findings implicate this <italic>MMP3</italic> polymorphism as a contributor to ESCC susceptibility.</p></sec></body><back><ack><title>Acknowledgments</title><p>We thank Xu Quan Yang for providing samples and clinical information.</p></ack><fn-group><fn id="fn9-medscimonit-20-2269"><p><bold>Disclosure statement</bold></p><p>No competing financial interests exist.</p></fn><fn id="fn10-medscimonit-20-2269"><p><bold>Source of support:</bold> This work was supported by grants from the China Medical Board in New York, the Application Foundation of Sichuan Province (no. 03JY029-089-2) and the Emphatic Programme of Sichuan Province (no. 2006Z09-007-4), China</p></fn></fn-group><ref-list><title>References</title><ref id="b1-medscimonit-20-2269"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parkin</surname><given-names>DM</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><etal/></person-group><article-title>Global cancer statistics, 2002</article-title><source>Cancer J Clin</source><year>2005</year><volume>55</volume><fpage>74</fpage><lpage>108</lpage></element-citation></ref><ref id="b2-medscimonit-20-2269"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klimstra</surname><given-names>DS</given-names></name></person-group><article-title>Pathologic prognostic factors in esophageal carcinoma</article-title><source>Semin Oncol</source><year>1994</year><volume>21</volume><fpage>425</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">8042040</pub-id></element-citation></ref><ref id="b3-medscimonit-20-2269"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>YT</given-names></name><name><surname>McLaughlin</surname><given-names>JK</given-names></name><name><surname>Blot</surname><given-names>WJ</given-names></name><etal/></person-group><article-title>Risk factors for esophageal cancer in Shanghai. China. I. Role of cigarette smoking and alcohol drinking</article-title><source>Int J Cancer</source><year>1994</year><volume>58</volume><fpage>192</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">8026880</pub-id></element-citation></ref><ref id="b4-medscimonit-20-2269"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Parkin</surname><given-names>DM</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><etal/></person-group><article-title>Time trends in cancer mortality in China: 1987&#x02013;1999</article-title><source>Int J Cancer</source><year>2003</year><volume>106</volume><fpage>771</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">12866039</pub-id></element-citation></ref><ref id="b5-medscimonit-20-2269"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoner</surname><given-names>GD</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name></person-group><article-title>Etiology and chemoprevention of esophageal squamous cell carcinoma</article-title><source>Carcinogenesis</source><year>2001</year><volume>22</volume><fpage>1737</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">11698334</pub-id></element-citation></ref><ref id="b6-medscimonit-20-2269"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Launoy</surname><given-names>G</given-names></name><name><surname>Milan</surname><given-names>CH</given-names></name><name><surname>Faivre</surname><given-names>J</given-names></name><etal/></person-group><article-title>Alcohol, tobacco and oesophageal cancer: effects of the duration of consumption, mean intake and current and former consumption</article-title><source>Br J Cancer</source><year>1997</year><volume>75</volume><fpage>1389</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">9155065</pub-id></element-citation></ref><ref id="b7-medscimonit-20-2269"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parsons</surname><given-names>SL</given-names></name><name><surname>Watson</surname><given-names>SA</given-names></name><name><surname>Brown</surname><given-names>PD</given-names></name><etal/></person-group><article-title>Matrix metalloproteinases</article-title><source>Br J Surg</source><year>1997</year><volume>84</volume><fpage>160</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">9052425</pub-id></element-citation></ref><ref id="b8-medscimonit-20-2269"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>GI</given-names></name><name><surname>Duncan</surname><given-names>ME</given-names></name><name><surname>O&#x02019;Neil</surname><given-names>P</given-names></name><etal/></person-group><article-title>Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer</article-title><source>J Pathol</source><year>1998</year><volume>185</volume><fpage>256</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">9771478</pub-id></element-citation></ref><ref id="b9-medscimonit-20-2269"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shima</surname><given-names>I</given-names></name><name><surname>Sasaguri</surname><given-names>Y</given-names></name><name><surname>Kusukawa</surname><given-names>J</given-names></name><etal/></person-group><article-title>Production of matrix metalloproteinase-2 and metalloproteinase-3 related to malignant behavior of esophageal carcinoma</article-title><source>Cancer</source><year>1992</year><volume>70</volume><fpage>2747</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">1451050</pub-id></element-citation></ref><ref id="b10-medscimonit-20-2269"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanioka</surname><given-names>Y</given-names></name><name><surname>Yoshida</surname><given-names>T</given-names></name><name><surname>Yagawa</surname><given-names>T</given-names></name><etal/></person-group><article-title>Matrix metalloproteinase-7 and matrix metalloproteinase-9 are associated with unfavourable prognosis in superficial oesophageal cancer</article-title><source>Br J Cancer</source><year>2003</year><volume>89</volume><fpage>2116</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">14647147</pub-id></element-citation></ref><ref id="b11-medscimonit-20-2269"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujimoto</surname><given-names>T</given-names></name><name><surname>Parry</surname><given-names>S</given-names></name><name><surname>Urbanek</surname><given-names>M</given-names></name><etal/></person-group><article-title>A single nucleotide polymorphism in the matrix metalloproteinase-1 (MMP-1) promoter influences amnion cell MMP-1 expression and risk for preterm premature rupture of the fetal membranes</article-title><source>J Biol Chem</source><year>2002</year><volume>277</volume><fpage>6296</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">11741975</pub-id></element-citation></ref><ref id="b12-medscimonit-20-2269"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>S</given-names></name><name><surname>Watts</surname><given-names>GF</given-names></name><name><surname>Mandalia</surname><given-names>S</given-names></name><etal/></person-group><article-title>Genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis</article-title><source>Br Heart J</source><year>1995</year><volume>73</volume><fpage>209</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">7727178</pub-id></element-citation></ref><ref id="b13-medscimonit-20-2269"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Ye</surname><given-names>S</given-names></name><name><surname>Herrmann</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis</article-title><source>Circulation</source><year>1999</year><volume>99</volume><fpage>1788</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">10199873</pub-id></element-citation></ref><ref id="b14-medscimonit-20-2269"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghilardi</surname><given-names>G</given-names></name><name><surname>Biondi</surname><given-names>ML</given-names></name><name><surname>Caputo</surname><given-names>M</given-names></name><etal/></person-group><article-title>A single nucleotide polymorphism in the matrix metalloproteinase-3 promoter enhances breast cancer susceptibility</article-title><source>Clin Cancer Res</source><year>2002</year><volume>8</volume><fpage>3820</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">12473595</pub-id></element-citation></ref><ref id="b15-medscimonit-20-2269"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hinoda</surname><given-names>Y</given-names></name><name><surname>Okayama</surname><given-names>N</given-names></name><name><surname>Takano</surname><given-names>N</given-names></name><etal/></person-group><article-title>Association of functional polymorphisms of matrix metalloproteinase (MMP)-1 and MMP-3 genes with colorectal cancer</article-title><source>Int J Cancer</source><year>2002</year><volume>102</volume><fpage>526</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">12432557</pub-id></element-citation></ref><ref id="b16-medscimonit-20-2269"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirata</surname><given-names>H</given-names></name><name><surname>Naito</surname><given-names>K</given-names></name><name><surname>Yoshihiro</surname><given-names>S</given-names></name><etal/></person-group><article-title>A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter is associated with conventional renal cell carcinoma</article-title><source>Int J Cancer</source><year>2003</year><volume>106</volume><fpage>372</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">12845675</pub-id></element-citation></ref><ref id="b17-medscimonit-20-2269"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugimoto</surname><given-names>M</given-names></name><name><surname>Yoshida</surname><given-names>S</given-names></name><name><surname>Kennedy</surname><given-names>S</given-names></name><etal/></person-group><article-title>Matrix metalloproteinase-1 and -9 promoter polymorphisms and endometrial carcinoma risk in a Japanese population</article-title><source>J Soc Gynecol Investig</source><year>2006</year><volume>13</volume><fpage>523</fpage><lpage>29</lpage></element-citation></ref><ref id="b18-medscimonit-20-2269"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>X</given-names></name><name><surname>Kuang</surname><given-names>G</given-names></name><name><surname>Wei</surname><given-names>LZ</given-names></name><etal/></person-group><article-title>No association of the matrix metalloproteinase 1 promoter polymorphism with susceptibility to esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma in northern China</article-title><source>World J Gastroenterol</source><year>2005</year><volume>11</volume><fpage>2385</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">15832405</pub-id></element-citation></ref><ref id="b19-medscimonit-20-2269"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Jin</surname><given-names>X</given-names></name><name><surname>Fang</surname><given-names>S</given-names></name><etal/></person-group><article-title>The functional SNP in the matrix metalloproteinase-3 promoter modifies susceptibility and lymphatic metastasis in esophageal squamous cell carcinoma but not in gastric cardiac adenocarcinoma</article-title><source>Carcinogenesis</source><year>2004</year><volume>25</volume><fpage>2519</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">15319302</pub-id></element-citation></ref><ref id="b20-medscimonit-20-2269"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Luo</surname><given-names>H</given-names></name><etal/></person-group><article-title>Association of matrix metalloproteinases-9 gene polymorphisms with genetic susceptibility to esophageal squamous cell carcinoma</article-title><source>DNA Cell Biol</source><year>2008</year><volume>27</volume><fpage>553</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">18680431</pub-id></element-citation></ref><ref id="b21-medscimonit-20-2269"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stephens</surname><given-names>M</given-names></name><name><surname>Donnelly</surname><given-names>P</given-names></name></person-group><article-title>A comparison of bayesian methods for haplotype reconstruction from population genotype data</article-title><source>Am J Hum Genet</source><year>2003</year><volume>73</volume><fpage>1162</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">14574645</pub-id></element-citation></ref><ref id="b22-medscimonit-20-2269"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deryugina</surname><given-names>EI</given-names></name><name><surname>Quigley</surname><given-names>JP</given-names></name></person-group><article-title>Matrix metalloproteinases and tumor metastasis</article-title><source>Cancer Metastasis Rev</source><year>2006</year><volume>25</volume><fpage>9</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">16680569</pub-id></element-citation></ref><ref id="b23-medscimonit-20-2269"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Egeblad</surname><given-names>M</given-names></name><name><surname>Werb</surname><given-names>Z</given-names></name></person-group><article-title>New functions for the matrix metalloproteinases in cancer progression</article-title><source>Nat Rev Cancer</source><year>2002</year><volume>2</volume><fpage>161</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">11990853</pub-id></element-citation></ref><ref id="b24-medscimonit-20-2269"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>CL</given-names></name><name><surname>Matrisian</surname><given-names>LM</given-names></name></person-group><article-title>Matrilysin: an epithelial matrix metalloproteinase with potentially novel functions</article-title><source>Int J Biochem Cell Biol</source><year>1996</year><volume>28</volume><fpage>123</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">8729000</pub-id></element-citation></ref><ref id="b25-medscimonit-20-2269"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tetlow</surname><given-names>LC</given-names></name><name><surname>Lees</surname><given-names>M</given-names></name><name><surname>Woolley</surname><given-names>DE</given-names></name></person-group><article-title>Comparative studies of collagenase and stromelysin-1 expression by rheumatoid synoviocytes <italic>in vitro</italic></article-title><source>Virchows Arch</source><year>1995</year><volume>425</volume><fpage>569</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">7697212</pub-id></element-citation></ref><ref id="b26-medscimonit-20-2269"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johansson</surname><given-names>N</given-names></name><name><surname>Ahonen</surname><given-names>M</given-names></name><name><surname>K&#x000e4;h&#x000e4;ri</surname><given-names>VM</given-names></name></person-group><article-title>Matrix metalloproteinases in tumor invasion</article-title><source>Cell Mol Life Sci</source><year>2000</year><volume>57</volume><fpage>5</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">10949577</pub-id></element-citation></ref><ref id="b27-medscimonit-20-2269"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>S</given-names></name></person-group><article-title>Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome</article-title><source>Cardiovasc Res</source><year>2006</year><volume>69</volume><fpage>636</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">16122719</pub-id></element-citation></ref><ref id="b28-medscimonit-20-2269"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li&#x000e8;vre</surname><given-names>A</given-names></name><name><surname>Milet</surname><given-names>J</given-names></name><name><surname>Carayol</surname><given-names>J</given-names></name><etal/></person-group><article-title>Genetic polymorphisms of MMP1, MMP3 and MMP7 gene promoter and risk of colorectal adenoma</article-title><source>BMC Cancer</source><year>2006</year><volume>6</volume><fpage>270</fpage><pub-id pub-id-type="pmid">17125518</pub-id></element-citation></ref><ref id="b29-medscimonit-20-2269"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okamoto</surname><given-names>K</given-names></name><name><surname>Ishida</surname><given-names>C</given-names></name><name><surname>Ikebuchi</surname><given-names>Y</given-names></name><etal/></person-group><article-title>The genotypes of IL-1 beta and MMP-3 are associated with the prognosis of HCV-related hepatocellular carcinoma</article-title><source>Intern Med</source><year>2010</year><volume>49</volume><fpage>887</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">20467172</pub-id></element-citation></ref><ref id="b30-medscimonit-20-2269"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>S</given-names></name><name><surname>Jin</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><etal/></person-group><article-title>Polymorphisms in the MMP1 and MMP3 promoter and non-small cell lung carcinoma in North China</article-title><source>Carcinogenesis</source><year>2005</year><volume>26</volume><fpage>481</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">15528217</pub-id></element-citation></ref><ref id="b31-medscimonit-20-2269"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krippl</surname><given-names>P</given-names></name><name><surname>Langsenlehner</surname><given-names>U</given-names></name><name><surname>Renner</surname><given-names>W</given-names></name><etal/></person-group><article-title>The 5A/6A Polymorphism of the Matrix Metalloproteinase 3 Gene Promoter and Breast Cancer</article-title><source>Clin Cancer Res</source><year>2004</year><volume>10</volume><fpage>3518</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">15161710</pub-id></element-citation></ref><ref id="b32-medscimonit-20-2269"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lei</surname><given-names>H</given-names></name><name><surname>Zaloudik</surname><given-names>J</given-names></name><name><surname>Vorechovsky</surname><given-names>I</given-names></name></person-group><article-title>Lack of association of the -1171(5A) allele of the MMP3 promoter with breast cancer</article-title><source>Clin Chem</source><year>2002</year><volume>48</volume><fpage>798</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">11978619</pub-id></element-citation></ref><ref id="b33-medscimonit-20-2269"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Jin</surname><given-names>X</given-names></name><name><surname>Fang</surname><given-names>S</given-names></name><etal/></person-group><article-title>The functional SNP in the matrix metalloproteinase-3 promoter modifies susceptibility and lymphatic metastasis in esophageal squamous cell carcinoma but not in gastric cardiac adenocarcinoma</article-title><source>Carcinogenesis</source><year>2004</year><volume>25</volume><fpage>2519</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">15319302</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="t1-medscimonit-20-2269" position="float"><label>Table 1</label><caption><p>Primer sequences and reaction conditions for MMP polymorphism detection.</p></caption><table frame="hsides" rules="rows"><thead><tr><th valign="middle" align="center" rowspan="1" colspan="1">Gene polymorphim size (bp)</th><th valign="middle" align="center" rowspan="1" colspan="1">Primer sequence</th><th valign="middle" align="center" rowspan="1" colspan="1">Annealing temperature</th><th valign="middle" align="center" rowspan="1" colspan="1">Restriction enzyme</th><th valign="middle" align="center" rowspan="1" colspan="1">Product</th></tr></thead><tbody><tr><td valign="middle" rowspan="2" align="left" colspan="1">MMP1 &#x02212;1607 1G/2G</td><td valign="top" align="left" rowspan="1" colspan="1">F: TGACTTTTAAAACATAGTCTATGTTCA</td><td valign="middle" rowspan="2" align="center" colspan="1">51&#x000b0;C</td><td valign="middle" rowspan="2" align="center" colspan="1">AluI</td><td valign="top" align="center" rowspan="1" colspan="1">2G: 269</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">R: TCTTGGATTGATTTGAGATAAGTCATAGC</td><td valign="top" align="center" rowspan="1" colspan="1">1G: 241 +28</td></tr><tr><td valign="middle" rowspan="2" align="left" colspan="1">MMP3 &#x02212;1612 5A/6A</td><td valign="top" align="left" rowspan="1" colspan="1">F: GGTTCTCCATTCCTTTGATGGGGGGAAAGA</td><td valign="middle" rowspan="2" align="center" colspan="1">65&#x000b0;C</td><td valign="middle" rowspan="2" align="center" colspan="1">TthIII</td><td valign="top" align="center" rowspan="1" colspan="1">6A: 130</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">R: CTTCCTGGAATTCACATCACTGCCACCACT</td><td valign="top" align="center" rowspan="1" colspan="1">5A: 96 +34</td></tr><tr><td valign="middle" rowspan="2" align="left" colspan="1">MMP9 &#x02212;1562C/T</td><td valign="top" align="left" rowspan="1" colspan="1">F: ATGGCTCATGCCCGTAATC</td><td valign="middle" rowspan="2" align="center" colspan="1">62&#x000b0;C</td><td valign="middle" rowspan="2" align="center" colspan="1">SphI</td><td valign="top" align="center" rowspan="1" colspan="1">C: 352</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">R: TCACCTTCTTCAAAGCCCTATT</td><td valign="top" align="center" rowspan="1" colspan="1">T: 208 +144</td></tr></tbody></table></table-wrap><table-wrap id="t2-medscimonit-20-2269" position="float"><label>Table 2</label><caption><p>Characteristics of study subjects.</p></caption><table frame="hsides" rules="rows"><thead><tr><th valign="middle" align="center" rowspan="1" colspan="1">Group</th><th valign="middle" align="center" rowspan="1" colspan="1">Controls<break/>n=132 (%)</th><th valign="middle" align="center" rowspan="1" colspan="1">ESCC patients<break/>n=132 (%)</th><th valign="middle" align="center" rowspan="1" colspan="1">Significance</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Age (years)</td><td valign="top" align="center" rowspan="1" colspan="1">60.4 &#x000b1;8.42</td><td valign="top" align="center" rowspan="1" colspan="1">60.0 &#x000b1;9.33</td><td valign="top" align="center" rowspan="1" colspan="1">.55<xref ref-type="table-fn" rid="tfn1-medscimonit-20-2269">*</xref></td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1">Gender</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Male</td><td valign="top" align="center" rowspan="1" colspan="1">83 (62.88)</td><td valign="top" align="center" rowspan="1" colspan="1">74 (56.06)</td><td valign="top" align="center" rowspan="1" colspan="1">.26<xref ref-type="table-fn" rid="tfn2-medscimonit-20-2269">**</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Female</td><td valign="top" align="center" rowspan="1" colspan="1">49 (37.12)</td><td valign="top" align="center" rowspan="1" colspan="1">58 (43.94)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td colspan="4" valign="top" align="left" rowspan="1">Smoking</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Smoker</td><td valign="top" align="center" rowspan="1" colspan="1">56 (42.42)</td><td valign="top" align="center" rowspan="1" colspan="1">63 (47.73)</td><td valign="top" align="center" rowspan="1" colspan="1">.39<xref ref-type="table-fn" rid="tfn2-medscimonit-20-2269">**</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Non-smoker</td><td valign="top" align="center" rowspan="1" colspan="1">76 (57.58)</td><td valign="top" align="center" rowspan="1" colspan="1">69 (52.27)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tfn1-medscimonit-20-2269"><label>*</label><p><italic>p</italic> value for t-test;</p></fn><fn id="tfn2-medscimonit-20-2269"><label>**</label><p>Value for &#x003c7;<sup>2</sup>-test.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3-medscimonit-20-2269" position="float"><label>Table 3</label><caption><p>Genotype and allele frequencies of three SNPs in the MMPs gene between ESCC patients and controls.</p></caption><table frame="hsides" rules="rows"><thead><tr><th valign="middle" align="center" rowspan="1" colspan="1">Polymorphisms</th><th valign="middle" align="center" rowspan="1" colspan="1">Controls n=132 (%)</th><th valign="middle" align="center" rowspan="1" colspan="1">ESCC patients n=132 (%)</th><th valign="middle" align="center" rowspan="1" colspan="1">OR (95% CI)</th><th valign="middle" align="center" rowspan="1" colspan="1">p</th></tr></thead><tbody><tr><td colspan="5" valign="top" align="left" rowspan="1"><italic>MMP1</italic> &#x02212;1607 1G/2G</td></tr><tr><td colspan="5" valign="top" align="left" rowspan="1">Genotypes</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;2G2G</td><td valign="top" align="right" rowspan="1" colspan="1">87 (65.91)</td><td valign="top" align="right" rowspan="1" colspan="1">81 (61.36)</td><td valign="top" align="right" rowspan="1" colspan="1">1.00 (Ref)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;2G1G</td><td valign="top" align="right" rowspan="1" colspan="1">40 (30.30)</td><td valign="top" align="right" rowspan="1" colspan="1">41 (31.06)</td><td valign="top" align="right" rowspan="1" colspan="1">1.10 (0.65&#x02013;1.87)</td><td valign="top" align="center" rowspan="1" colspan="1">.72</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;1G1G</td><td valign="top" align="right" rowspan="1" colspan="1">5 (3.9)</td><td valign="top" align="right" rowspan="1" colspan="1">10 (7.58)</td><td valign="top" align="right" rowspan="1" colspan="1">2.15 (0.70&#x02013;6.55)</td><td valign="top" align="center" rowspan="1" colspan="1">.17</td></tr><tr><td colspan="5" valign="top" align="left" rowspan="1">Alleles</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;2G</td><td valign="top" align="right" rowspan="1" colspan="1">214 (84.47)</td><td valign="top" align="right" rowspan="1" colspan="1">203 (76.89)</td><td valign="top" align="right" rowspan="1" colspan="1">1.00 (Ref)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;1G</td><td valign="top" align="right" rowspan="1" colspan="1">50 (15.53)</td><td valign="top" align="right" rowspan="1" colspan="1">61 (23.11)</td><td valign="top" align="right" rowspan="1" colspan="1">1.29 (0.85&#x02013;1.96)</td><td valign="top" align="center" rowspan="1" colspan="1">.24</td></tr><tr><td colspan="5" valign="top" align="left" rowspan="1"><italic>MMP3</italic> &#x02212;1612 5A/6A</td></tr><tr><td colspan="5" valign="top" align="left" rowspan="1">Genotypes</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;6A6A</td><td valign="top" align="right" rowspan="1" colspan="1">65 (49.24)</td><td valign="top" align="right" rowspan="1" colspan="1">40 (30.30)</td><td valign="top" align="right" rowspan="1" colspan="1">1.00 (Ref)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;6A5A</td><td valign="top" align="right" rowspan="1" colspan="1">61 (46.21)</td><td valign="top" align="right" rowspan="1" colspan="1">72 (54.55)</td><td valign="top" align="right" rowspan="1" colspan="1">1.92 (1.14&#x02013;3.23)</td><td valign="top" align="center" rowspan="1" colspan="1">.01</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;5A5A</td><td valign="top" align="right" rowspan="1" colspan="1">6 (4.55)</td><td valign="top" align="right" rowspan="1" colspan="1">20 (15.15)</td><td valign="top" align="right" rowspan="1" colspan="1">5.42 (2.01&#x02013;14.63)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;.001</td></tr><tr><td colspan="5" valign="top" align="left" rowspan="1">Alleles</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;6A</td><td valign="top" align="right" rowspan="1" colspan="1">191 (72.35)</td><td valign="top" align="right" rowspan="1" colspan="1">152 (57.58)</td><td valign="top" align="right" rowspan="1" colspan="1">1.00 (Ref)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;5A</td><td valign="top" align="right" rowspan="1" colspan="1">73 (27.65)</td><td valign="top" align="right" rowspan="1" colspan="1">112 (42.42)</td><td valign="top" align="right" rowspan="1" colspan="1">1.93 (1.34&#x02013;2.77)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;.001</td></tr><tr><td colspan="5" valign="top" align="left" rowspan="1"><italic>MMP9</italic> &#x02212;1562 C/T</td></tr><tr><td colspan="5" valign="top" align="left" rowspan="1">Genotypes</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;CC</td><td valign="top" align="right" rowspan="1" colspan="1">92 (69.70)</td><td valign="top" align="right" rowspan="1" colspan="1">84 (63.64)</td><td valign="top" align="right" rowspan="1" colspan="1">1.00 (Ref)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;CT</td><td valign="top" align="right" rowspan="1" colspan="1">34 (37.98)</td><td valign="top" align="right" rowspan="1" colspan="1">38 (28.79)</td><td valign="top" align="right" rowspan="1" colspan="1">1.22 (0.71&#x02013;2.12)</td><td valign="top" align="center" rowspan="1" colspan="1">.47</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;TT</td><td valign="top" align="right" rowspan="1" colspan="1">6 (4.01)</td><td valign="top" align="right" rowspan="1" colspan="1">10 (7.58)</td><td valign="top" align="right" rowspan="1" colspan="1">1.85 (0.64&#x02013;5.24)</td><td valign="top" align="center" rowspan="1" colspan="1">.26</td></tr><tr><td colspan="5" valign="top" align="left" rowspan="1">Alleles</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;C</td><td valign="top" align="right" rowspan="1" colspan="1">218 (82.58)</td><td valign="top" align="right" rowspan="1" colspan="1">206 (78.03)</td><td valign="top" align="right" rowspan="1" colspan="1">1.00 (Ref)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;T</td><td valign="top" align="right" rowspan="1" colspan="1">46 (17.42)</td><td valign="top" align="right" rowspan="1" colspan="1">58 (21.97)</td><td valign="top" align="right" rowspan="1" colspan="1">1.33 (0.87&#x02013;2.05)</td><td valign="top" align="center" rowspan="1" colspan="1">.19</td></tr></tbody></table><table-wrap-foot><fn id="tfn3-medscimonit-20-2269"><p>Ref &#x02013; reference category.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t4-medscimonit-20-2269" position="float"><label>Table 4</label><caption><p>Haplotype distribution in the patients with ESCC and controls.</p></caption><table frame="hsides" rules="rows"><thead><tr><th valign="middle" align="center" rowspan="1" colspan="1">Haplotype</th><th valign="middle" align="center" rowspan="1" colspan="1">Controls n=264 (%)</th><th valign="middle" align="center" rowspan="1" colspan="1">ESCC patients n=264 (%)</th><th valign="middle" align="center" rowspan="1" colspan="1">OR (95% CI)</th><th valign="middle" align="center" rowspan="1" colspan="1">p</th></tr></thead><tbody><tr><td valign="top" align="center" rowspan="1" colspan="1">2G-6A</td><td valign="top" align="right" rowspan="1" colspan="1">146 (55.30)</td><td valign="top" align="right" rowspan="1" colspan="1">104 (39.6)</td><td valign="top" align="right" rowspan="1" colspan="1">1.00 (Ref)</td><td valign="top" align="right" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="center" rowspan="1" colspan="1">2G-5A</td><td valign="top" align="right" rowspan="1" colspan="1">68 (25.80)</td><td valign="top" align="right" rowspan="1" colspan="1">99 (37.30)</td><td valign="top" align="right" rowspan="1" colspan="1">2.04 (1.37&#x02013;3.04)</td><td valign="top" align="right" rowspan="1" colspan="1">&#x0003c;.01</td></tr><tr><td valign="top" align="center" rowspan="1" colspan="1">1G-6A</td><td valign="top" align="right" rowspan="1" colspan="1">45 (17.10)</td><td valign="top" align="right" rowspan="1" colspan="1">48 (18.00)</td><td valign="top" align="right" rowspan="1" colspan="1">1.50 (0.98&#x02013;2.42)</td><td valign="top" align="right" rowspan="1" colspan="1">.01</td></tr><tr><td valign="top" align="center" rowspan="1" colspan="1">1G-5A</td><td valign="top" align="right" rowspan="1" colspan="1">5 (1.90)</td><td valign="top" align="right" rowspan="1" colspan="1">13 (5.10)</td><td valign="top" align="right" rowspan="1" colspan="1">3.65 (1.26&#x02013;10.55)</td><td valign="top" align="right" rowspan="1" colspan="1">.01</td></tr></tbody></table></table-wrap></floats-group></article>
